Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Update on Tozadenant Trial for Parkinson’s

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.


On 11/15/17, Acorda Therapeutics, Inc. announced that several people living with Parkinson's who participated in the Phase III trial for tozadenant experienced agranulocytosis — a severe drop in the number of white blood cells which fight infection — leading to cases of sepsis and five fatalities. Participants in the trial will now have blood cell count monitoring increased from monthly to weekly.  The study has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

Tozadenant is an oral adenosine A2a receptor antagonist currently in Phase III development as an adjunctive treatment to levodopa in Parkinson’s disease patients to reduce OFF time.

Statement from the Parkinson’s Foundation

Our thoughts are with the family members who lost a loved one enrolled in this trial. Their participation in clinical research will ultimately help make life better for the people diagnosed with Parkinson's in the future. 

The Parkinson’s Foundation remains confident that Acorda and the FDA will investigate this rare event. Clinical trials in Parkinson’s disease — from oral therapies to surgical treatments — have had a strong safety record and they are critical in testing the safety and efficacy of investigational therapies.

In order to discover new PD therapies, we rely on brave and altruistic people, like the ones in this trial, to participate in clinical research. The Parkinson’s Foundation remains committed to supporting clinical research through our global network of Centers of Excellence and Parkinson’s Advocates in Research.

If you would like more information about the benefits and risks of clinical trial participation, learn more here.  If you have questions or concerns, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).

Thursday, November 16, 2017
Parkinson's Disease Foundation to Host Celebrate Spring New York on Thursday, April 7
Friday, March 18, 2016

The Young New Yorkers for the Fight Against Parkinson’s and the Parkinson’s Disease Foundation® (PDF®) will hold its ninth annual Celebrate Spring New York at Marquee located at 289 10th Avenue between 26th and 27th Streets in New York City on Thursday, April 7, 2016.   Proceeds from the evening will support PDF’s research programs.

PDF Champions Raise More Than $35,000 for Parkinson’s Research at Martinis & Bellinis Event
Monday, March 7, 2016

Norwood, NJ, resident Stephanie Goldman-Pittel and her fellow co-chairs from nearby communities raised more than $35,000 to benefit the Parkinson’s Disease Foundation (PDF) at Martinis & Bellinis, their third annual PDF Helping Hours event on March 3. More than 100 guests attended the event held at Harvest Bistro & Bar in Closter, NJ, to support Parkinson’s research.

Parkinson's Disease Foundation Launches Online Course for Occupational Therapy Practitioners
Tuesday, March 1, 2016

The Parkinson's Disease Foundation® (PDF®) is pleased to launch a new online course, Occupational Therapy: Across the Parkinson's Disease Continuum, to prepare occupational therapy practitioners who are caring for the growing population of people living with Parkinson's disease.

Parkinson's Disease Foundation Invests in Next Generation of Nursing Leaders
Wednesday, February 24, 2016

The Parkinson's Disease Foundation® (PDF®) is pleased to announce eight new training opportunities for nursing faculty as part of The Edmond J. Safra Visiting Nurse Faculty Program at PDF. The program improves nursing care in Parkinson's disease (PD) by training nurse faculty leaders who in turn, prepare their students to fight the disease on the front lines.

PDF Champions to Host Martinis & Bellinis for Parkinson’s Research at Harvest Bistro & Bar in Closter, NJ, on Thursday, March 3
Tuesday, January 26, 2016

WHAT:  Norwood, NJ, resident Stephanie Goldman-Pittel is inviting her community to Harvest Bistro & Bar in Closter, NJ, for post-work cocktails to support the Parkinson’s cause. She and her fellow co-chairs from nearby communities are hosting Martinis & Bellinis, their third annual Helping Hours event to benefit the Parkinson’s Disease Foundation (PDF) on Thursday, March 3 from 7:00 PM to 10:00 PM.

PDF Mourns the Passing of Joel Gerstel
Tuesday, January 26, 2016

The Parkinson’s Disease Foundation (PDF) mourns the loss of Joel Gerstel, a long-time friend and partner in the Parkinson’s community. Mr. Gerstel, who served as President and CEO of the American Parkinson Disease Association (APDA) until 2012, passed away on January 21 at the age of 80.

NPF and PDF Sign Letter of Intent to Merge
Monday, January 25, 2016

John W. Kozyak, Chair of the Board of the National Parkinson Foundation (NPF) and Howard D. Morgan, Chair of Board of the Parkinson’s Disease Foundation (PDF), released the following statement today:

The National Parkinson Foundation’s Moving Day® Walks Fund $1.25 Million in Parkinson’s Programs in 2015
Monday, December 14, 2015

MIAMI — The National Parkinson Foundation (NPF) is proud to announce that Moving Day®, A Walk for Parkinson’s, has funded $1.25 million in mission services in 2015 to make life better for people living with Parkinson’s.

The National Parkinson Foundation Answers 50,000 Helpline Calls
Monday, November 23, 2015

MIAMI — The National Parkinson Foundation (NPF) announced today that their toll-free Helpline, 1-800-4PD-INFO, has achieved a major milestone: the Helpline reached its 50,000th caller.

The Edmond J. Safra National Parkinson’s Wellness Initiative Expands to Chicago and Tampa
Tuesday, November 10, 2015

National Initiative to Improve the Quality of Life for People with Parkinson’s
 

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.